Categories: News

LRQA Ignites Cybersecurity Conversations at CISO Singapore 2025

SINGAPORE, Aug. 25, 2025 /PRNewswire/ — LRQA made a powerful impact on August 19 and 20 at CISO Singapore 2025, where over 400 cybersecurity leaders gathered to shape the future of digital defence. Held at the iconic Marina Bay Sands, the two-day event was a melting pot of innovation, strategy, and collaboration — and LRQA was right at the heart of it.

- Advertisement -

LRQA’s booth was a vibrant hub of insight, where the expert team shared practical, cutting-edge strategies on cyber resilience, adaptive security, and breach readiness, drawing strong interest from attendees across the industry.

- Advertisement -

The event’s key themes aligned perfectly with LRQA’s mission to empower organizations with smarter, stronger security frameworks:

- Advertisement -
  • Cyber Resilience: Unmasking threats and aligning security with business goals.
  • Adaptive Security: Staying ahead of emerging risks with agile, tech-forward defense strategies.
  • Risk Governance: Building robust governance models that empower teams and mitigate threats.
  • Breach Readiness: Equipping businesses to detect, respond, and recover with confidence.

“CISO Singapore was more than just an event, it was a catalyst for meaningful conversations and future-forward thinking,” said Fotis Kampouris, Executive Vice President – Asia Pacific, LRQA. “It’s inspiring to see our team connecting with so many passionate professionals who are driving meaningful change in cybersecurity.”

- Advertisement -

LRQA’s presence underscored its commitment to helping organizations navigate the complexities of today’s threat landscape with clarity and confidence. As the cybersecurity world continues to evolve, LRQA remains a trusted partner in building resilient, adaptive, and governance-driven security ecosystems.

- Advertisement -

About LRQA

- Advertisement -

LRQA, is a leading global assurance provider bringing together expertise in brand assurance, certification, cybersecurity, inspection, and training – to help its customers negotiate a rapidly changing world. Operating in more than 120 countries and recognised by over 30 accreditation bodies worldwide, LRQA covers almost every sector, helping customers around the world to manage risk.

- Advertisement -

For more information, visit https://www.lrqa.com/ 

- Advertisement -

Media Contact:
Hasan Surve

Regional Marketing Manager – APAC, LRQA

hasan.surve@lrqa.com 

Photo: https://mma.prnewswire.com/media/2756965/LRQA.jpg
Logo: https://mma.prnewswire.com/media/1994890/5391521/LRQA_Logo.jpg

- Advertisement -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/lrqa-ignites-cybersecurity-conversations-at-ciso-singapore-2025-302537568.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

4 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

4 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

4 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

4 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

4 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

4 hours ago